PHIOGEN, a pioneering startup developing next-generation bacteriophage-based therapeutics, has appointed Dr. Mayukh Das as Chief Operations Officer (COO).
Dr. Das joins PHIOGEN from Johnson & Johnson Innovative Medicine where he served as Associate Scientific Director of Phage Microbiology and brings with him more than 19 years’ experience managing medical research and pharmaceutical product development. Dr. Das, who holds a PhD in Molecular Microbiology, has also patented and successfully commercialized award-winning technology and has hands-on experience preparing regulatory submissions to the Food and Drug Administration (FDA) on behalf of biotech and large pharma.
As the COO, Dr. Das will be responsible for overseeing the strategic direction and operational efficiency of the company’s phage-based research and development. His deep understanding of drug discovery processes, coupled with proficiency in navigating regulatory landscapes will play a key role in advancing PHIOGEN’s therapeutic pipeline.
Commenting on his appointment, Dr. Das said: “It’s a very exciting time to be joining the PHIOGEN management team and having the opportunity to contribute to the development of some truly transformative phage treatments. I’m looking forward to working with PHIOGEN’s already impressive and dynamic team, alongside the innovative high-throughput technology platform they have developed. I’m particularly drawn to PHIOGEN’s mission because it aligns with my passion for shaping the future of healthcare by delivering high-performing phage products for the hardest to treat and most critical infections.”
PHIOGEN CEO, Amanda Burkardt, said: “We are very pleased to welcome Dr. Das to our team. This is a significant appointment for PHIOGEN that will further expand our platform’s capabilities and help implement strategies to manage the company’s accelerating growth. His arrival underscores our dedication to bringing our phage products to the market and strategically developing antimicrobial solutions for wide-scale use.”
The company is a spin-off from Baylor College of Medicine at the Texas Medical Center and was born out of scientific discovery at TAILOR Labs. Launched on June 1st 2023, PHIOGEN unveiled its innovative technology platform at the 6th World Conference on Targeting Phage Therapy in Paris, where the team was presented with the ‘Best Scientific Innovation Award’.
PHIOGEN’s novel therapeutics have already been administered to patients in FDA approved compassionate use cases where conventional antibiotics have stopped working. The company’s breakthrough in bacteriophage technology overcomes the challenge of resistance, opening a commercial pathway for phage therapy in which single biological products are capable of treating large-scale patient populations.
– ENDS –
PHIOGEN™ is a trademark of PHIOGEN INC. PHIOGEN is an innovative biotech company housed in the Texas Medical Center’s Innovation Hub and is committed to using its breakthrough technology to deliver bacteriophage products that tackle some of the most deadly bacterial infections suffered by patients across the globe. PHIOGEN’s state-of-the-art and patented process has generated proof of concept through several in vivo studies as well as use in patients under FDA approved compassionate use cases.
For more information: www.phiogenpharma.com